Clinical Trials Logo

Heart Diseases clinical trials

View clinical trials related to Heart Diseases.

Filter by:

NCT ID: NCT04001283 Recruiting - Clinical trials for Coronary Artery Disease

Nitrite Effects on Cardiac Muscle in CABG

Start date: January 21, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test whether sodium nitrite affects the expression of cellular proteins important for metabolic and vascular function in vascular offcuts and cardiac biopsies taken from patients undergoing coronary artery bypass grafting (CABG) surgery.

NCT ID: NCT03999463 Completed - Clinical trials for Ischemic Heart Disease

Sevoflurane Effect on Left Atrial Performance: A Transoesophageal Echocardiographic Study

Start date: July 1, 2019
Phase:
Study type: Observational [Patient Registry]

The left atrial performance is affected by the preload as well as the afterload. The LA active pumping is increased by stretching of the LA but within limits, after which the active pumping declines. The LV stiffness acts as the LA afterload. Whenever the LV stiffness increases, the overall emptying fraction becomes more pumpdependent

NCT ID: NCT03999320 Completed - Clinical trials for Congenital Heart Disease

Sophrology and Congenital Heart Disease

SOPHRO CARE
Start date: July 19, 2019
Phase: N/A
Study type: Interventional

The SOPHRO-CARE trial aims to measure the impact of sophrology on exercise capacity of adolescents and young adults with congenital heart disease. Investigator hypothesized that a series of group sessions of sophrology may improve the exercise capacity, in this population.

NCT ID: NCT03997201 Completed - Clinical trials for Ischemic Heart Disease

Ripple Mapping Guided Ablation of Ischaemic Ventricular Tachycardia.

RIPPLE-VT
Start date: April 18, 2019
Phase: N/A
Study type: Interventional

The Ripple VT-1 Study is a prospective clinical trial that aims to investigate if catheter ablation of ventricular tachycardia in patients with ischaemic heart disease can be effectively performed using Ripple Mapping.

NCT ID: NCT03997097 Withdrawn - Clinical trials for Pulmonary Hypertension

Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease

VU-INHIB
Start date: June 1, 2023
Phase: Phase 3
Study type: Interventional

In univentricular hearts, selective lung vasodilators such as phosphodiesterase type 5 (PDE5) inhibitors would decrease pulmonary resistance and improve exercise tolerance. However, the level of evidence for the use of PDE5 inhibitors in patients with a single ventricle (SV) remains limited. the investigators present the SV-INHIBITION study rationale, design and methods.The SV-INHIBITION trial is a nationwide multicentre, randomised, double blind, placebo-controlled, phase III study, aiming to evaluate the efficacy of sildenafil on the ventilatory efficiency during exercise, in teenagers and adult patients (>15 y.o.) with a SV. Patients with pulmonary arterial hypertension (mean pulmonary arterial pressure (mPAP) > 15 mmHg and trans-pulmonary gradient > 5 mmHg) measured by cardiac catheterisation, will be eligible. The primary outcome is the variation of the VE/VCO2 slope, measured by a cardiopulmonary exercise test, between baseline and 6 months of treatment. A total of 50 patients are required to observe a decrease of 5 ± 5 points in the VE/VCO2 slope, with a power of 90% power and an alpha risk of 5%. The secondary outcomes are: clinical outcomes, 6 minute walk test, SV function, NT Pro BNP, VO2max, stroke volume, mPAP, trans-pulmonary gradient, SF36 quality of life score, safety and acceptability. This study aims to answer the question whether PDE5 inhibitors should be prescribed in patients with a SV. This trial has been built focusing on the 3 levels of research defined by the WHO: disability (exercise tolerance), deficit (SV function), and handicap (quality of life).

NCT ID: NCT03991910 Recruiting - Clinical trials for Rheumatic Heart Disease

The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients

Start date: June 27, 2019
Phase: Phase 3
Study type: Interventional

Objective propose: to investigate the effect of Ramipril in suppressing ST2 (suppression of tumorigenicity 2) in the cardiac mitral valve in patients with Rheumatic Heart Disease. We hypothesized that we hypothesized that ramipril will improve rheumatic mitral valve fibrosis through the downregulation of ST2.

NCT ID: NCT03989700 Not yet recruiting - Heart Diseases Clinical Trials

Effect of Thiamin Supplementation on Thiamin Status in Children With Heart Disease Receiving Diuretic Drugs

Start date: July 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine effect of thiamin supplementation on thiamin status by measuring thiamin pyrophosphate effect in children with heart disease receiving diuretic drugs.

NCT ID: NCT03988166 Completed - Clinical trials for Ischemic Heart Disease

Chronic Total Occlusion Percutaneous Coronary Intervention Study

CTO-PCI
Start date: May 20, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate angiographic confirmation of placement of any guidewire beyond the CTO, in the true vessel lumen, in patients undergoing CTO percutaneous coronary intervention (PCI) in which at least one Teleflex guidewire and at least one Turnpike catheter are used.

NCT ID: NCT03986281 Completed - Hypertension Clinical Trials

A Pilot Study to Assess the Accuracy of Blood Pressure Assessment by the Omron HeartGuide Smartwatch

Start date: May 20, 2019
Phase: N/A
Study type: Interventional

The accuracy of devices like the recent FDA-clearance of the Omron HeartGuideā„¢ Blood Pressure sensor in robust clinical settings remain in question and thus form the underpinning of this research study. The objective of this pilot prospective study is to assess the accuracy of the Omron Blood Pressure sensor as compared to arterial line blood pressure monitoring.

NCT ID: NCT03984006 Completed - Heart Failure Clinical Trials

Early Detection of Autoimmune Thyroid Heart Disease Via Urinary Exosomal Proteins

Start date: June 28, 2019
Phase:
Study type: Observational

Autoimmune thyroid disease revealed close relationship with heart failure, including the entities of subclinical hyperthyroidism and hypothyroidism. Heart failure is a principal complication of all forms of heart disease. The American College of Cardiology defines HF as a complex clinical syndrome that impairs the ability of the ventricle to fill with or inject blood. In fact, it may be caused by a defect in myocardial contraction, by an impairment in ventricular filling with preserved systolic function ('diastolic HF') or by a combination of both. Earlier detection of probable trend of heart failure in subclinical thyroid diseases is very important in not only Taiwan, Pan-Asia, but all over the aging world. However, it is not currently available. The investigators will enroll 20 patients with subclinical hyperthyroidism, subclinical hypothyroidism, and collect their urine specimens in outpatient clinic per year. Prognostic biological markers via this prospective study. The study was designed as prospective pattern, and the investigators will enroll clinical and subclinical thyroid disease with quarterly follow-up, then detect urine exosomal proteins NT-proBNP. The investigators try to find the correlation of outcome with unknown/fresh biomarkers in this study with time-dependent manner. The investigators hope to find earlier predicting biomarkers for heart dysfunction in autoimmune thyroid disease.